Chai Discovery has successfully completed a $130 million Series B financing round aimed at accelerating its research and product development in the realm of artificial intelligence (AI)-driven antibody design. This funding will bolster the company’s efforts to create a comprehensive computer-aided design suite for molecular therapeutics, positioning it at the forefront of innovation in drug discovery.
Utilizing its proprietary Chai-2 platform, Chai Discovery claims to be the first zero-shot generative system to achieve double-digit success rates in de novo antibody design. The platform’s capabilities were showcased in a recent preprint, reporting a 16% success rate across a diverse set of targets, a significant leap from traditional computational methods. This rapid workflow from AI design to wet-lab validation within two weeks underscores the platform’s potential to streamline therapeutic development.
As the company continues to expand its capabilities, the implications of this funding are profound. With a total valuation of $1.3 billion, Chai Discovery is positioned to redefine the landscape of therapeutic design, harnessing AI to create antibodies with desirable therapeutic attributes before any laboratory experiments are conducted. This paradigm shift could lead to faster, more efficient drug discovery processes, ultimately addressing unmet clinical needs more effectively.
Open the full market picture for your next decision →
